Compared to the control, the nanocarrier was also shown to inhibit tumor growth in vivo, demonstrating an almost 20‐fold higher level of p53 expression in tumors treated with the dual‐therapeutic p53 and DOX‐loaded DNA‐NS. Here, TP53 is linked to neoplasm.